The L-type calcium channel blocker, isradipine, attenuates cue-induced cocaine-seeking by enhancing dopaminergic activity in the ventral tegmental area to nucleus accumbens pathway

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Nii A AddyAnjali M Rajadhyaksha

Abstract

Previous preclinical and clinical investigations have focused on the L-type calcium channel (LTCC) as a potential therapeutic target for substance abuse. While some clinical studies have examined the ability of LTCC blockers to alter cocaine's subjective effects, very few LTCC studies have examined cocaine relapse. Here, we examined whether ventral tegmental area (VTA)-specific or systemic administration of the LTCC inhibitor, isradipine, altered cocaine-seeking behavior in a rat model. Male Sprague-Dawley rats first received 10 days of cocaine self-administration training (2 h sessions), where active lever depression resulted in delivery of a ∼0.5 mg/kg cocaine infusion paired with a tone + light cue. Rats then underwent 10 days of forced abstinence, without access to cocaine or cocaine cues. Rats were then returned to the opertant chamber for the cue-induced cocaine-seeking test, where active lever depression in the original training context resulted in tone + light cue presentation. We found VTA specific or systemic isradipine administration robustly attenuated cocaine-seeking, without altering cocaine-taking nor natural reward seeking. Dopamine (DA) signaling in the nucleus accumbens (NAc) core is necessary and sufficient f...Continue Reading

References

Aug 7, 1999·Journal of Psychoactive Drugs·R MalcolmD Kajdasz
Sep 3, 2002·Neuroscience·B I HylandR Miller
Apr 11, 2003·Nature·Paul E M PhillipsRegina M Carelli
Sep 6, 2003·Pharmacology, Biochemistry, and Behavior·Mehmet SofuogluAlison Oliveto
Jun 23, 2004·Journal of Clinical Psychopharmacology·Bankole A JohnsonJames B Mauldin
Aug 27, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Anjali RajadhyakshaBarry E Kosofsky
Dec 22, 2005·Experimental and Clinical Psychopharmacology·John D RoacheWilliam L Murff
Mar 28, 2008·Drug and Alcohol Review·James Shearer
Aug 18, 2009·Pharmacology & Therapeutics·Noushin Yahyavi-Firouz-Abadi, Ronald E See
Sep 24, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kathryn SchierberlAnjali M Rajadhyaksha
Jun 15, 2013·Current Opinion in Neurobiology·Rajita Sinha
Aug 30, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Benjamin T SaundersTerry E Robinson
Oct 4, 2013·Journal of Neurophysiology·Jessica L KorandaXiaoxi Zhuang
Oct 22, 2013·Neuroscience and Biobehavioral Reviews·Anna B KonovaRita Z Goldstein
Jun 4, 2015·Channels·Nadine J Ortner, Jörg Striessnig
Sep 9, 2015·Psychopharmacology·Jonathan J CunninghamKaren Brebner
May 13, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Zeeba D KabirAnjali M Rajadhyaksha

❮ Previous
Next ❯

Citations

Apr 20, 2019·Journal of Neurochemistry·Michał KielbinskiWojciech B Solecki
Jun 28, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sarah E Swinford-Jackson, R Christopher Pierce
Jan 10, 2021·Journal of Neurochemistry·Rusty W NallAna-Clara Bobadilla

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies
dissection

Software Mentioned

Graph Pad Prism
SPSS
Demon Voltammetry and Analysis
FSCV

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.